Dear participants,

Welcome to the 8th International Cancer Immunotherapy and Immunomonitoring Conference!

This meeting is jointly organized by the International and Local Organizing Committees, and we have worked together to make this conference as informative and enjoyable as possible for you. We are looking forward to many superb presentations and discussions over the next few days that will allow you to consider new hypotheses and findings, present your own data and thoughts, and establish new collaborations and friendships. In addition to the outstanding basic and clinical science that will be presented, we hope that magnificent setting of the Hotel International close to the center of beautiful Bucharest will contribute to making this a very delightful and inspiring conference.

During this meeting, we will discuss cellular and molecular mechanisms of immune regulation in the tumor microenvironment that direct initiating and effector phases of antitumor immunity, as well control the efficacy and usefulness of anticancer immunotherapeutic modalities. We will also focus on recent clinical trial results and discuss the lessons we learned from preclinical evaluation of novel therapeutic approaches and immunomonitoring of patients with cancer receiving different modes of therapy. The special emphasis will be placed on topics presenting new ideas on how to improve the efficacy of cancer treatment, including combined chemo-radiation-immunotherapy, immunomodulators, and new targets for therapy. Invited plenary speakers and speakers selected from submitted abstracts, as well as session chairs will provide a framework for discussion. This will offer participants a unique opportunity to evaluate the field of tumor immunology and immunotherapy from different perspectives and might recommend new ways of solving existing problems and difficulties.

We hope that we have assembled one of the preeminent conferences on CITIM topics and we anticipate that the plenary sessions, short talks, poster presentations and after-the-meeting discussions will stimulate a breakthrough in our understanding of how to improve the efficiency of immunotherapy for cancer. If we can be of any assistance, please do not hesitate to call upon us. Please enjoy the meeting!

 

Sincerely,

CITIM-2025 Organizers

DOI: https://doi.org/10.3889/seejim.2025.8.CITIM

Published: 2025-03-17

Correlation of the tumor HLA-I expression (with LOH-HLA) with the immune response and clinical outcomes in NSCLC patients after perioperative neoadjuvant chemo-immunotherapy

Natalia Aptsiauri , Francisco Perea, Marta Molina-Alejandre , Federico Garrido, Mariano Provencio , Francisco Ruiz-Cabello , Alberto Cruz-Bermúdez

029

Cancer Therapeutic Strategies to Rewire Tumor Microenvironment

Laura Patras, Alina Sesarman, Giorgiana Negrea, Stefan-Mihai Dragan, Marta-Szilvia Meszaros, Emilia Licarete, Valentin Florian Rauca, Lavinia Luput, Marius Alupei, Alina Porfire, Manuela Banciu

030

Novel Drugs Targeting for Immunogenic Cancer Cell Death

Galyna Bila, Anton Arkhypov, Insa Klemt, Andriy Mokhir, Rostyslav Bilyy

032

Neutrophil Extracellular Traps (NETs) in cancer and beyond

Nuha Al-Sharif, Mohamad Qaisi, Naomi Kaisar, Dan Padawer, Osnath Bohana, Yael Volman, Zvi G. Fridlender

036

The role of NETs and their aggregates in disease.

Maximilian Dölling, Christine Schauer, Martin Herrmann

038

Deciphering immune tumor subtypes through microenvironment profiling

Agata Mlynska, Egle Zymantaite, Austeja Butkute, Neringa Dobrovolskiene, Jan Aleksander Krasko, Olha Karaman, Karolina Suveizde, Beatrice Gudaite, Margarita Zvirble, Emilija Paberale, Nijole Matuseviciene, Vita Pasukoniene

043

Insights in genetic and epigenetic traits in cutaneous melanoma - new therapy targets

Monica Neagu, Dobre Elena-Georgiana , Carolina Constantin, Mihaela Surcel, Adriana Munteanu, Sabina Zurac

044

Myeloid-derived Suppressor Cells EN-RAGE Antitumor Immunity

Suzanne Ostrand-Rosenberg, Tom Huecksteadt , Karl Sanders

046

Immunomonitoring of patients with hepatic cancer undergoing liver transplantation after immunotherapy unravels an unexpected synergism between trained immunity and T cell memory.

Licia Rivoltini, Sherrie Bhoori, Michela Dosi, Francesca Rini, Luca Lalli, Stefano Bergamini, Agata Cova, Elena Daveri, Veronica Huber, Martina Stroscia, Paola Frati, Vincenzo Mazzaferro

049

The tumor immune microenvironment as a target for nano-therapies and patient-tailored treatments.

Luca Vannucci, L Rajsiglova, D Stakheev , P Lukac, P Tenti, L Sushystskyi , M Babic, K Krausova, K Kalkusova, P Taborska, L Sojka, P Makovicky , PP Ceci , E Falvo, J Svoboda , D Hadraba , D Vondrasek , G Mucciolo , P Cappello, D Smrz

052

The role of tumor microenvironment IL-1β in Colorectal Cancer

Noy Machluf-Kaz, Sami Stalin, Guy Barsky, Marina Bersudsky, Ron N. Apte, Lelyan Moadi, Sondra Turjeman, Omri Koren, Elena Voronov

053

Targeting Metabolic Programming in the Tumor Microenvironment

Jonathan M. Weiss, Erika M. Palmieri, Marieli Gonzalez-Cotto, Ian A. Bettencourt, Shilpa Kurian, Barry O’Keefe, Daniel W. McVicar

054

A new pathway towards immunotherapy-supported radiology for targeted Boron Neutron Capture Therapy (BNCT)

Klaus M. Spohr, Gabriel P. Bleotu, Mirabela Cristea, Domenico Doria, Alexandra Ivan, Marius Jurca, Vincent Lelasseux, Cristina Marin, Viorel Nastasa, Valentin Ordodi, Virgil Paunescu, Mara Popovici, Silviu Stanciu, Stefan Stoenescu, Calin Tatu, Ada Telea, Chieh-jen Yang, Maria-Iulia Zai

057

Tissue transglutaminase as a new immunomodulatory target in ovarian cancer tumor microenvironment

Livia E. Sima, Siqi Chen , Horacio Cardenas, Guangyuan Zhao, Yinu Wang, Cristina Ivan, Hao Huang, Bin Zhang , Daniela Matei

058

LL-37: A powerful booster of ex vivo-prepared DC-based vaccines in prostate cancer patients and the TRAMP mouse model, without additional benefit from anti-PD1 therapy

Kateřina Krausová, Dmitry Stakheev, Pavla Táborská, Milan Reiniš, Romana Mikyšková, Michal Podrazil, Jiřina Bartůňková, Daniel Smrž

061

CD19 Chimeric Antigen Receptor (CAR) modified cytokine killer cells compared to classical CD19 CAR-T: advantages and disadvantages

Olha Karaman, Madeline Kim, Gina Scurti, Jan Aleksander Kraśko, Oliwia Bochnacka, Suzanne Quinn, Vita Pasukoniene, Michael I. Nishimura

062

Investigating RUNX2 KO in B16 melanoma cells as a potential strategy to enhance in vivo tumor response to therapeutic approaches

Elena-Georgiana Dobre, Mauro Voi, Elisa Orlandi, Carola de Martinis , Carolina Constantin, Donato Zipeto, Maria-Teresa Valenti, Monica Neagu

065

Influence of stemness inhibitors on the immunomodulatory properties of colorectal cancer

Austeja Butkute, Marius Baltramonaitis, Simona Malmige, Adas Darinskas, Vita Pasukoniene, Agata Mlynska

068

Adipokines and gut microbiome shape the outcome of cutaneous melanoma: preliminary insights

Carolina Constantin, Elena-Georgiana Dobre, Adriana Narcisa Munteanu, Mihaela Surcel, Sabina Andrada Zurac, Monica Neagu

069

Toll Like Receptor 7/8 agonists antitumor effects on NK cells in murine melanoma model

Gheorghita Isvoranu, Mihaela Surcel, Adriana Narcisa Munteanu, Ana-Maria Enciu, Marioara Chiritoiu-Butnaru, Gabriela Chiritoiu, Cristian Munteanu, Monica Neagu

072

Inhibition of dendritic cell maturation in 3D and 2D colon carcinoma cell models

Pavol Lukáč, Lenka Rajsiglová, Dmitry Stakheev, Paolo Tenti, Kateřina Krausová, Leonid Sushytskyi, Daniel Smrž, Luca Vannucci

073

Molecular mechanisms of communication between innate immune cells and vascular cells in cancer and cardiovascular diseases

Razvan D Macarie, Monica M Tucureanu, Letitia Ciortan, Mihaela Vadana, Andreea Mihaila, Miruna L Naie, Ana Maria Gan, Ileana Manduteanu, Elena Butoi

074

Depletion of Myeloid Cells Reduces Tumorigenesis Driven by a High-Protein Diet in a Colitis-Associated Cancer Model

Veronika Motúzová, Janaina L S Donadio, Michal Kraus, Štěpán Coufal, Maliha Rizwan, Miloslav Kverka

076

Immunomodulatory properties of nickel-doped ferric-based nanoparticles in vitro

Lenka Rajsiglova, Dmitry Stakheev, Katerina Krausova, Pavol Lukac, Paolo Tenti, Michal Babic, Daniel Smrž, Luca Vannucci

077

Innovative Vanadium (V)-Based Drug: Preliminary In Vitro and In Vivo Antitumor Investigations

Mihaela Turtoi, Maria Anghelache, Geanina Voicu, Florentina Safciuc, Mariana Deleanu, Manuela Călin

078

Establishment of cancer immunotherapy in vitro model

Jana Veprkova, Andrej Besse, Lenka Sedlarikova, Lenka Besse

079

Collagen IV-Targeted Nanoparticles for Cardiac Tumor Drug Delivery

Geanina Voicu, Florentina Safciuc, Cristina Ana Mocanu, Ruxandra Anton, Manuela Calin

080

Soluble PD-1/PD-L1 in prostate cancer: immune cell associations and clinical implications

Margarita Žvirblė, Žilvinas Survila, Neringa Dobrovolskiene, Agata Mlynska, Vita Pašukonienė

081